In a nutshell This study investigated the safety and effectiveness of palbociclib (Ibrance) in geriatric patients. They found that this treatment was well-tolerated and effective in these patients. Some background Breast cancer (BC) is one of the most common cancers. There are many subtypes of BC. The most common form is hormone...
Read More
In a nutshell This study evaluated whether adding carboplatin (Paraplatin) to chemotherapy improved survival for patients with triple-negative breast cancer (TNBC). This study found that this treatment combination improved long-term survival without tumor growth or spread in these patients. Some background TNBC is a type...
Read More
In a nutshell This study evaluated the effectiveness of durvalumab (Imfinzi) combined with chemotherapy for patients with triple-negative breast cancer (TNBC). This study found that more patients treated with durvalumab had a complete disappearance of all signs of cancer (complete response) compared to placebo. Some...
Read MoreIn a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read More
In a nutshell This study investigated if a prognostic tool called EndoPredict can predict the success of treatment in hormone receptor-positive breast cancer (BC). They found that high scores using EndoPredict predicted treatment benefit in patients with BC. Some background Breast cancer (BC) is one of the most common cancers. BC treatment...
Read More
In a nutshell This study investigated the safety and effectiveness of intraoperative radiotherapy (IORT; radiotherapy during surgery) in early breast cancer (BC). They found that tumor recurrence was low after IORT. Some background Early breast cancer (BC) can be treated using different approaches. Most patients undergo breast-conserving therapy...
Read MoreIn a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...
Read MoreIn a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read More
In a nutshell This study investigated the effect of neoadjuvant chemotherapy (NAC; chemotherapy before surgery) in patients undergoing oncoplastic breast-conserving surgery (OBCS). They found that NAC did not affect the rate of complications in OBCS. Some background Breast cancer (BC) can be treated using a number of strategies....
Read More
In a nutshell This study evaluated how well palbociclib (Ibrance) works in patients with breast cancer who received multiple lines of previous therapy. This study found that palbociclib was effective for these patients. Some background There are several different treatments for breast cancer depending on the types of...
Read More
In a nutshell This study evaluated whether treating breast cancer that has not been completely removed with more surgery was more effective than non-surgical options such as chemotherapy. This study found that there was no difference in outcomes between treating with further surgery versus treating with a non-surgical option. Some...
Read MoreIn a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read More
